CRIANN boosts bandwidth in French research and education network with Adtran FSP 3000
5.11.2024 11:00:00 EET | Business Wire | Press release
Adtran today announced that the Centre Régional Informatique et d’Applications Numériques de Normandie (CRIANN) is using its FSP 3000 optical transport technology and ALM fiber monitoring platform to boost the capacity and resilience of its research and education network, thanks to the financial support of the Normandy Region. By integrating Adtran’s solution, the Normandy-based supercomputing center and provider of high-performance digital infrastructure is ensuring faster and more reliable connectivity for the region’s scientific and academic institutions. Adtran’s Elite partner Axians also played a key role in the installation and continues to deliver maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104047734/en/
Adtran’s technology is helping CRIANN drive high-speed, secure and ultra-reliable connectivity throughout its research and education network. (Photo: Business Wire)
“Our fiber network promotes innovation and the advancement of scientific knowledge. We support academic institutions in several ways, including by enabling data-intensive simulations and AI research for which high-speed, secure and ultra-reliable connectivity is fundamental,” said Alain Bidaud, CTO of CRIANN. “Harnessing Adtran’s optical transport technology, we’ve boosted capacity across our fiber infrastructure while also rendering our services more resilient. The FSP 3000 enables a seamless transition from our existing transport network. What’s more, its modular architecture radically simplifies the upgrade process so we can augment the solution to efficiently and sustainably meet future demand.”
This major upgrade to CRIANN’s research and education network increases bandwidth across all three of its sites. Featuring Adtran’s FSP 3000 OpenFabric™ 1200, the new solution integrates an open and flexible OTN fabric with DWDM transponder functions that deliver up to 400Gbit/s per wavelength and supports multiple OTN and Ethernet client services from 10Gbit/s to 400Gbit/s on a single card. This enables CRIANN to boost transport capacity and ensures the network can easily scale to meet both current and future demands.
CRIANN has also deployed Adtran’s ALM in-service fiber monitoring platform, which provides rapid, detailed alerts in the event of any fiber disruption. Combined with Adtran’s Mosaic Network Controller and Fiber Director, it offers a sophisticated real-time geographic information system that delivers pinpoint accuracy in locating fiber issues. By empowering CRIANN’s maintenance team with a precise understanding of its fiber infrastructure, the technology helps reduce truck rolls, improves network availability and minimizes operating costs.
“Built on our FSP 3000 platform, CRIANN’s upgraded fiber infrastructure is ideally suited to meet the growing demands of research and education networks for higher capacity and greater reliability,” commented Stuart Broome, GM of EMEA sales at Adtran. “Harnessing our OpenFabric™ 1200 switchponder, the new solution supports Ethernet and OTN services up to 400Gbit/s. This technology simplifies operations and maximizes the potential of CRIANN’s fiber assets. With its new, robust network, CRIANN is empowering Normandy’s academic community to take their research to whole new levels.”
“At Axians, we believe in forging connections that matter, not just with technology but also through relationships. Our partnership with CRIANN and Adtran is a testament to this philosophy. Together, we’re ensuring CRIANN’s research and education network can adapt, evolve and meet future challenges,” noted Bruno Durand, GM of Axians communication and cloud Caen. “This deployment is about providing top-tier opportunities for scientists, teachers and students. By merging technical expertise with our commitment to delivering excellence, we’re ensuring that the region stays at the cutting edge of research and innovation.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104047734/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom